Revisiting malignant hypertension: rationale and design of the 'HAMA cohort', on behalf of the ESH working group 'hypertension and the kidney'.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
1
2
2023
medline:
25
3
2023
entrez:
31
1
2023
Statut:
ppublish
Résumé
Malignant hypertension has not disappeared and is associated with a poor prognosis. Yet, so far, it has received limited attention from the medical community. Guidelines are mainly based on expert consensus and low quality evidences. We set up a prospective, multicenter, observational cohort of patients with malignant hypertension. We collect at admission medical history, demographic data, ongoing treatment, clinical parameters, symptoms, care pathways, target organ status and at discharge and during follow up treatment administrated, adverse events, blood pressure level, target organ status. We aim to recruit 500 patients with malignant hypertension in 5 years, with a 5-year follow-up. Our primary objective is to assess the 5 years prognosis of these patients. The HAMA (Hypertension Arterielle MAligne, meaning malignant hypertension) registry aims to describe the epidemiology and to assess the prognosis of malignant hypertension in a contemporary multidisciplinary cohort, with emphasis on the diversity of current management and care pathway among the different medical specialties. It may help improving our pathophysiological knowledge, and pave the way to update the definition of this particular form of hypertension. The multidisciplinary network developed in the wake of this project is expected to facilitate the set up therapeutic trials, laying the ground for evidence-based recommendations.
Sections du résumé
BACKGROUND
Malignant hypertension has not disappeared and is associated with a poor prognosis. Yet, so far, it has received limited attention from the medical community. Guidelines are mainly based on expert consensus and low quality evidences.
METHOD
We set up a prospective, multicenter, observational cohort of patients with malignant hypertension. We collect at admission medical history, demographic data, ongoing treatment, clinical parameters, symptoms, care pathways, target organ status and at discharge and during follow up treatment administrated, adverse events, blood pressure level, target organ status. We aim to recruit 500 patients with malignant hypertension in 5 years, with a 5-year follow-up. Our primary objective is to assess the 5 years prognosis of these patients.
DISCUSSION
The HAMA (Hypertension Arterielle MAligne, meaning malignant hypertension) registry aims to describe the epidemiology and to assess the prognosis of malignant hypertension in a contemporary multidisciplinary cohort, with emphasis on the diversity of current management and care pathway among the different medical specialties. It may help improving our pathophysiological knowledge, and pave the way to update the definition of this particular form of hypertension. The multidisciplinary network developed in the wake of this project is expected to facilitate the set up therapeutic trials, laying the ground for evidence-based recommendations.
Identifiants
pubmed: 36719959
doi: 10.1097/HJH.0000000000003357
pii: 00004872-990000000-00170
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
453-458Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Paini A, Aggiusti C, Bertacchini F, Rosei CA, Maruelli G, Arnoldi C, et al. Definitions and epidemiological aspects of hypertensive urgencies and emergencies. High Blood Press Cardiovasc Prev 2018; 25:241–244.
Murphy FD, Grill J. So called malignant hypertension: a clinical and morphologic study. JAMA 1930; 46:75–104.
Vohlard F, Fahr KT. Die Brightsche Krankheit, Klinik, Pathologie und Atlas. J Spinger 1914; 210–246.
Kimmelstiel P, Wilson C. Benign and malignant hypertension and nephrosclerosis: a clinical and pathological study. Am J Pathol 1936; 12:45–83.
Van den born B-J, Koopmans R, Groeneveld J, Van Montfrans G. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens 2006; 24:2299–2304.
Shantsila A, Lip GYH. Malignant hypertension revisited — does this still exist? Am J Hypertens 2017; 30:543–549.
Cremer A, Amraoui F, Lip GYH, Morales E, Rubin S, Segura J, et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens 2016; 30:463–466.
González R, Morales E, Segura J, Ruilope LM, Praga M. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant 2010; 25:3266–3272.
Amraoui F, Van Der Hoeven NV, Van Valkengoed IGM, Vogt L, Van Den Born B-JH. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case–control study. J Clin Hypertens (Greenwich) 2014; 16:122–126.
Gosse P, Coulon P, Papaioannou G, Litalien J, Lemetayer P. Impact of malignant arterial hypertension on the heart. J Hypertens 2011; 29:798–802.
Lip GY1, Beevers MBD. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens 1995; 13:915.
Lane Da, Lip GYH, Beevers DG. Improving survival of malignant hypertension patients over 40 years. Am J Hypertens 2009; 22:1199–1204.
Rubin S, Cremer A, Boulestreau R, Rigothier C, Kuntz S, Gosse P. Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. J Hypertens 2018; 36:1–9.
Polgreen LA, Suneja M, Tang F, Carter BL, Polgreen PM. Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. Hypertension 2015; 65:1002–1007.
Van den Born B, Lip GYH, Brguljan-hitij J, Cremer A, Segura J, Morales E, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Hear J Cardiovasc Pharmacother 2019; 5:37–46.
Gosse P, Boulestreau R, Brockers C, Puel C, Rubin S, Cremer A. The pharmacological management of malignant hypertension. J Hypertens 2020; 38:2325–2330.
Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the Use of Echocardiography in Adult Hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE) †. J Am Soc Echocardiogr 2015; 28:727–754.
Stergiou GS, Palatini P, Parati G, O’Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021; 39:293–1302.
Shantsila A, Shantsila E, Beevers DG, Lip GYH. Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry. J Hypertens 2017; 35:2310–2314.
Wang R, Laveskog A, Laukka EJ. MRI load of cerebral microvascular lesions and neurodegeneration, cognitive decline, and dementia. Neurology 2018; 0:1487–1497.